1.	Phase I/II Study of Ras Peptide Cancer Vaccine With or Without Interleukin-2 in HLA-A2-1-Positive Patients With Locally Advanced or Metastatic Colorectal Cancer Phase: Phase II, Phase I Type: Treatment Status: Completed Age: Over 18 Sponsor: NCI Protocol IDs: NCI-99-C-0023L, NCI-T98-0034, NCT00019591, T98-0034
2.	Phase II Pilot Study of Tumor-Specific p53 or ras Vaccines With or Without Cellular Immunotherapy With Peptide-Activated Lymphocytes Plus Interleukin-2 in Patients With Tumors Expressing Mutant p53 or ras Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-95-C-0105A, NCI-T94-0096N, T94-0096, NCT00019084
3.	Phase II Study of Vaccine Therapy With Tumor-Specific Mutated Ras Peptides in Combination With Interleukin-2 and/or Sargramostim (GM-CSF) in Adults With Metastatic Solid Tumors Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-97-C-0141F, NCI-T96-0078, T96-0078, NCT00019331
4.	Phase I Pilot Study of Adjuvant Vaccine Therapy With Tumor-Specific Mutated ras Peptides in Patients With Colorectal, Pancreatic, Lung, Breast, or Prostate Cancer (Summary Last Modified 05/2002) Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-94-C-0096D, NCI-T93-0152N, T93-0152, NCT00019006
5.	Phase IB Study of Vaccination with a Recombinant Mutant ras Protein with the Immunologic Adjuvant QS21 in Patients with Adenocarcinomas Expressing an Activated ras Oncoprotein (Summary Last Modified 03/98) Phase: Phase I Type: Treatment Status: Closed Age: over 18 Sponsor: NCI Protocol IDs: NCI-97-C-0018, CRB-9411, NCI-NMOB-9608, NCI-T95-0048N, T95-0048
6.	Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome Phase: Phase I Type: Treatment Status: Completed Age: Over 17 Sponsor: NCI, Other Protocol IDs: CDR0000067158, MSKCC-98037, NCI-G99-1542, NCT00003959
7.	Phase I Pilot Study of Ras Peptide Cancer Vaccine and Sargramostim (GM-CSF) in Patients With Stage IB-IV Non-Small Cell Lung Cancer Phase: Phase I Type: Treatment Status: Completed Age: Over 17 Sponsor: NCI Protocol IDs: MSKCC-99028, NCI-G00-1775, NCT00005630
8.	Phase I Study of Ras Peptide Cancer Vaccine Plus Immunological Adjuvant QS21 in Patients With Advanced Pancreatic or Colorectal Adenocarcinoma (Summary Last Modified 06/2002) Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: FCCC-98026, NCI-T97-0051, NCT00006387, T97-0051